Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

Journal of Clinical Oncology

Volumn 21, Issue 16, 2003, Pages 3127-3132

  Yang, James C ^a   Sherry, Richard M ^a   Steinberg, Seth M ^a   Topalian, Suzanne L ^a   Schwartzentruber, Douglas J ^a   Hwu, Patrick ^a   Seipp, Claudia A ^a   Rogers Freezer, Linda ^a   Morton, Kathleen E ^a   White, Donald E ^a   Liewehr, David J ^a   Merino, Maria J ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG MEGADOSE; HUMAN; HYPOTENSION; KIDNEY CANCER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; FEMALE; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL;

CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0042914703     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.02.122     Document Type: Article

References (23)

1. Rosenberg SA, Lotze MT, Muul, L, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492, 1985
2. Lotze MT, Chang AE, Seipp CA, et al: High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: Responses, treatment-related morbidity and histologie findings. JAMA 256: 3117-3124, 1986
3. Rosenberg SA, Yang JC, White DE, et al: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Ann Surg 228:319, 1998
4. Fisher RI, Rosenberg SA, Sznol M, et al: High-dose aldesleukin in renal cell carcinoma: Long-term survival update. Cancer J Sci Am 3:S70-S72, 1997 (suppl 1)
5. Parkinson DR, Abrams JS, Wiernik PH, et al: Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 8:1650-1656, 1990
6. Atzpodien J, Korfer A, Evers, P, et al: Low dose subcutaneous recombinant interleukin-2 in advanced human malignancy: A phase II outpatient study. Mol Biother 2:18-26, 1990
7. Atzpodien J, Hanninen EL, Kirchner H, et al: Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13:497-501, 1995
8. Lissoni P, Barni S, Tancini, G, et al: Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Arch Ital Urol Androl 69:41-47, 1997
9. Sleijfer DT, Janssen RA, Buter, J, et al: Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10:1119-1123, 1992
10. Vogelzang NJ, Lipton A, and Figlin RA: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial. J Clin Oncol 9:1809-1816, 1993
11. Hanninen EL, Kirchner H, and Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients. J Urol 155:19-25, 1996
12. Ravaud A, Negrier S, Cany L, et al: Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J Cancer 69:1111-1114, 1994
13. Dutcher JP, Atkins M, Fisher R, et al: Interleukin-2-based therapy for metastatic renal cell cancer: The Cytokine Working Group experience, 1989-1997. Cancer J Sci Am 3:S73-S78, 1997 (suppl 1)
14. Yang JC, Topalian SL, Parkinson D, et al: Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: An interim report. J Clin Oncol 12:1572-1576, 1994
15. Yang JC, Rosenberg SA: An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am 3:S79-S84, 1997 (suppl 1)
16. Kovacs G, Akhtar M, Beckwith BJ, et al: The Heidelberg classification of renal cell tumours. J Pathol 183:131-133, 1997
17. Schwartzentruber D: Interleukin-2: Clinical Applications. Principles of Administration and Management of Side Effects, in Rosenberg, SA (ed.): Principles and Practice of the Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, Williams & Wilkins, 2000, pp 22-50
18. Kammula US, White DE, Rosenberg SA: Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 83:797-805, 1998
19. Phan GQ, Morton KE, Liewehr DJ, et al: Quality of life in patients with metastatic renal cell cancer receiving different regimens of interleukin-2. Proc Am Soc Clin Oncol 21:25a, 2002 (abstr)
20. McDermott D, Flaherty L, Clark J, et al: A Randomized Phase III Trial of High-Dose Interleukin-2 (HD IL2) Versus Subcutaneous (SC) 112/Interferon (IFN) in Patients with Metastatic Renal Cell Carcinoma (RCC). Proc Am Soc Clin Oncol 20:172, 2001 (abstr 685)
21. White RL, Jr, Schwartzentruber DJ, Guleria A, et al: Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 74:3212-3222, 1994
22. Phan GQ, Attia P, Steinberg SM, et al: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 19:3477-3482, 2001
23. Royal RE, Steinberg SM, Krouse RS, et al: Correlates of Response to IL-2 Therapy in Patients Treated for Metastatic Renal Cancer and Melanoma. Cancer J. Sci Am 2:91, 1996